YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra…
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"…
Anixa Biosciences ANIX has built a diversified oncology pipeline centered on two innovative platforms, cancer vaccines and cell-based immunotherapies. The company's lead programs include a breast cancer vaccine, an ovarian cancer vaccine,…
(RTTNews) - Anixa Biosciences Inc. (ANIX) presented encouraging final results from its Phase 1 clinical trial of its investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium (SABCS). Breast Cancer, particularly…
St. Petersburg, FL, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ: ANIX), held on…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANIXA BIOSCIENCES INC (ANIX) one of those stocks right now? By taking a look at the stock's year-to-d…
The U.S. stock market has experienced a volatile period, with major indices like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing varied performance amid ongoing trade tensions and impressive bank earnings. In this context, pe…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns…
September S&P 500 E-Mini futures (ESU25) are trending up +0.17% this morning, extending yesterday’s gains, while investors await a phone call between U.S. President Donald Trump and Chinese President Xi Jinping. Trump and Xi are scheduled…
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.02% this morning, taking a breather after yesterday’s gains, with investors turning their attention to an expected phone call betwe…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Solventum (SOLV) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance t…
* Anixa Biosciences (NASDAQ:ANIX [https://seekingalpha.com/symbol/ANIX]) filed $200M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10406401] MORE ON ANIXA BIOSCIENCES * Seeking Alpha’s Quant Rating on Anixa Biosciences…
* Anixa Biosciences (NASDAQ:ANIX [https://seekingalpha.com/symbol/ANIX]) said on Tuesday that the United States Patent and Trademark Office (USPTO) has issued a U.S. patent [https://seekingalpha.com/pr/20197516-anixa-biosciences-announces-…
SAN JOSE, Calif. - Anixa Biosciences, Inc. (NASDAQ:ANIX), a clinical-stage biotechnology company with a market capitalization of $94.7 million, announced Tuesday that the United States Patent and Trademark Office has issued a new patent fo…
This article summarizes the most significant insider buying and selling activities reported for US stocks on Thursday, July 31, 2025. Top Insider Buys: Old Market Capital Corp (NASDAQ:OMCC) saw its Chief Financial Officer Charles Krebs pur…
SAN JOSE, Calif. - Anixa Biosciences, Inc. (NASDAQ:ANIX), a $109.5 million market cap biotechnology company whose stock has surged nearly 46% year-to-date, announced Thursday that the United States Patent and Trademark Office will issue a…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANIXA BIOSCIENCES INC (ANIX) is a stock that can certainly grab the attention of many investors, but do…
SAN JOSE - Anixa Biosciences, Inc. (NASDAQ:ANIX), a $101 million market cap biotechnology company whose stock has surged nearly 40% over the past six months, announced Wednesday that the United States Patent and Trademark Office will issue…
Investing.com - H.C. Wainwright maintained its buy rating and $7.00 price target on Anixa Biosciences (NASDAQ:ANIX) following the company’s advancement in its ovarian cancer treatment trial. The clinical-stage biotech company operates in t…
SAN JOSE - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company with a market capitalization of approximately $109 million, has dosed the first patient in the fourth cohort of its Phase 1 clinical trial evaluating a chimeric ant…
ANIXA BIOSCIENCES ($ANIX) is expected to release its quarterly earnings data on Monday, June 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.10 per share. You can see Quiver Quantitative's $ANI…
On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:ANIX) breast cancer vaccine technology. Cleveland Clinic has exclusively license…
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ:CRSP), for example. Leading up to U.S. FDA rulings, the stock exploded from a low of about $37.50 to a high of $75. Granted, it di…
SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Gol…
The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy’s ability to recover from the recession without causing significant harm to the job market or sparking excessive inflation. She believes t…
SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic…
SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademar…
Gilead Sciences GILD announced the discontinuation of the late-stage ENHANCE study, a trial investigating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes (MDS). The ENHANCE study was a phase III randomi…
Shares of Vir Biotechnology VIR plunged 44.90% after the company announced that the mid-stage PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) study evaluating VIR-2482 for the prevention of symptomatic influenza A was unsuccessful. VI…
Halozyme Therapeutics, Inc. HALO announced that Roche RHHBY reported positive top-line results from its late-stage multiple sclerosis (MS) study evaluating a subcutaneous (SC) formulation of its drug Ocrevus (ocrelizumab). The SC formulati…
AVROBIO AVRO announced completing a review of its business encompassing the status of its programs, resources and capabilities as part of its reprioritization efforts. To this extent, the company has decided to halt the development program…
Novavax, Inc. NVAX has amended its advanced purchase agreement with the Canadian government per an announcement in a regulatory filing, which was published last week. The reason for the amendment was the Canadian government’s decision to r…
— Technology currently being evaluated for the treatment of ovarian cancer in Phase 1 clinical trial — SAN JOSE, Calif., July 11, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology compa…
ASLAN Pharmaceuticals ASLN reported top-line data from its phase IIb dose-ranging TREK-AD study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD). Eblasakimab, a novel monoclonal antibody, is an inhibitor of t…
ANIXA BIOSCIENCES INC (ANIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impa…
SAN JOSE, Calif., May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction with its partner Moffitt Cancer Center,…